Nektar Therapeutics buy BTIG Research
Start price
24.06.25
/
50%
€0.58
Target price
24.06.26
€86.27
Performance (%)
-
End price
25.06.26
-
Summary
This prediction was cancelled by the user.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 0.437% | 5.640% | 7.806% |
| iShares Nasdaq 100 | 1.057% | 0.282% | 27.239% |
| iShares Nikkei 225® | 1.769% | 0.406% | 49.266% |
| iShares S&P 500 | 0.368% | 1.920% | 22.336% |
Comments by BTIG_Research for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at BTIG Research from $60.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten
Current prediction by BTIG_Research for Nektar Therapeutics
Stopped prediction by BTIG_Research for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€1.17
30.09.24
30.09.24
€3.58
30.09.25
30.09.25
-50.21%
01.10.25
01.10.25
